Europe (WHO region) vs Vanuatu: Hepatitis B surface antigen (HBsAg) prevalence (%)
Europe (WHO region)
0.1%
in 2024
Vanuatu
1.8%
in 2024
Europe (WHO region) rank
10th
Vanuatu rank
13th
Hepatitis B surface antigen (HBsAg) prevalence (%) over time
- Europe (WHO region)
- Vanuatu
How they compare
Vanuatu currently reports 1.8% against 0.1% in Europe (WHO region), a difference of 1.7%.
That makes Vanuatu's figure about 18.0 times Europe (WHO region)'s.
Across all 10 years both countries report, Vanuatu has been ahead every year.
Europe (WHO region) ranks 10th and Vanuatu ranks 13th of 13 groups.
Vanuatu has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Europe (WHO region) | Vanuatu | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 1.6% | 1.5% | Vanuatu |
| 2020s | 0.1% | 1.7% | 1.6% | Vanuatu |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Europe (WHO region) or Vanuatu?
- Vanuatu, at 1.8% against 0.1% in Europe (WHO region) as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Europe (WHO region) and Vanuatu?
- 1.7%, with Vanuatu ahead.
- How many years of comparable data are there for Europe (WHO region) and Vanuatu?
- 10 years are reported by both, from 2015 to 2024.
- How do Europe (WHO region) and Vanuatu rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Europe (WHO region) ranks 10th and Vanuatu ranks 13th of 13 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.